Dr. Cameron R. Wolfe, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 105
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
NC license 2008-00913
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 274
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 104 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 52 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 121 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 106 |
| Dovato (dolutegravir sodium/lamivudine) | 64 |
| Tivicay (dolutegravir sodium) | 47 |
| Lisinopril Other prescribers in Durham, NC | 36 |
| Symtuza (darunavir/cob/emtri/tenof alaf) | 33 |
| Juluca (dolutegravir/rilpivirine) | 31 |
| Omeprazole Other prescribers in Durham, NC | 31 |
| Pravastatin Sodium Other prescribers in Durham, NC | 26 |
| Efavirenz-Emtric-Tenofov Disop (efavirenz/emtricit/tenofovr df) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 27 payments worth $46,576 in total to this clinician.
| Merck Sharp & Dohme LLC | $19,386 |
|---|---|
| Csl Behring | $18,600 |
| Janssen Research & Development, LLC | $4,950 |
| Briohealth Solutions, Inc. | $2,450 |
| AstraZeneca UK Limited | $1,074 |
| Abiomed | $116 |
| Consulting Fee | $27,074 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $15,660 |
| Travel and Lodging | $3,440 |
| Food and Beverage | $365 |
| Education | $36.55 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Csl Behring Feb 26, 2025 | Consulting Fee | $5,000 |
| Csl Behring Nov 4, 2025 | Consulting Fee | $5,000 |
| Csl Behring Jun 19, 2025 | Consulting Fee | $5,000 |
| Csl Behring Jul 3, 2025 | Consulting Fee Hizentra · Immunology | $3,600 |
| Merck Sharp & Dohme LLC Jan 30, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Greenville, SC · in-kind | $1,613 |
| Janssen Research & Development, LLC Feb 10, 2025 | Consulting Fee | $1,500 |
| Merck Sharp & Dohme LLC Mar 5, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to LANCASTER, SC · in-kind | $1,378 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Dec 15, 2025 | Consulting Fee | $1,074 |
| Briohealth Solutions, Inc. Dec 1, 2025 | Consulting Fee BRIOVAD · DURABLE MECHANICAL CIRCULATORY SUPPORT SYSTEM | $700 |
| Csl Behring Nov 4, 2025 | Consulting Fee | $5,000 |
| Janssen Research & Development, LLC Oct 8, 2025 | Consulting Fee | $1,050 |
| Briohealth Solutions, Inc. Sep 4, 2025 | Consulting Fee BRIOVAD · DURABLE MECHANICAL CIRCULATORY SUPPORT SYSTEM | $700 |
| Briohealth Solutions, Inc. Jul 23, 2025 | Consulting Fee BRIOVAD · DURABLE MECHANICAL CIRCULATORY SUPPORT SYSTEM | $350 |
| Csl Behring Jul 3, 2025 | Consulting Fee Hizentra · Immunology | $3,600 |
| Csl Behring Jun 19, 2025 | Consulting Fee | $5,000 |
| Janssen Research & Development, LLC Jun 11, 2025 | Consulting Fee | $1,350 |
| Janssen Research & Development, LLC May 5, 2025 | Consulting Fee | $1,050 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Winston-Salem, NC | $150 |
| Briohealth Solutions, Inc. Apr 20, 2025 | Consulting Fee BRIOVAD · DURABLE MECHANICAL CIRCULATORY SUPPORT SYSTEM | $700 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $10.85 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to LANCASTER, SC | $150 |
| Merck Sharp & Dohme LLC Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) PREVYMIS · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Mar 5, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to LANCASTER, SC · in-kind | $1,378 |
| Merck Sharp & Dohme LLC Mar 5, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Greenville, SC | $150 |
| Csl Behring Feb 26, 2025 | Consulting Fee | $5,000 |
| Janssen Research & Development, LLC Feb 10, 2025 | Consulting Fee | $1,500 |
| Merck Sharp & Dohme LLC Jan 30, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Greenville, SC · in-kind | $1,613 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $155,615 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ModernaTX, Inc. · Completed · NCT06067230 - An interventional efficacy and safety phase 3 randomized doubleblind 3ARM study to investigate ibuzatrelvir in adults with symptomatic COVID19 who are severely immunocompromised
Pfizer Inc. - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.